Juan A. Bueren Roncero

 

Unit: Complex disorders

E-mail: juan.bueren@ciemat.es

Phone: +34913466518

Prof Juan Bueren is Director of the Biomedical Innovation Unit (CIEMAT and Biomedical Network Centre for Research on Rare Diseases, CIBERER) and Co-ordinator of the Advanced Therapies Unit (IIS. Fundación Jiménez Díaz/CIEMAT). Dr Bueren currently serves as Vice-President of the European Society for Gene and Cell Therapy, is Member of the International Committee of the American Society for Gene and Cell Therapy, and is Consultant for Rocket Pharmaceuticals Inc. Dr Bueren is Scientific Director of two clinical gene therapy programs for patients with Fanconi anemia and Leukocyte Adhesion Deficiency Type I, respectively. Additionally has participated in the development of three therapeutic lentiviral vectors currently designed as Orphan Drugs by the European Medicines Agency and the FDA for the treatment of Fanconi anemia and other monogenic diseases. Dr Bueren has published more than 160 scientific papers in the field of stem cells and gene therapy, has been principal investigator and coordinator in 14 European Programs, has supervised more than 20 Doctoral Thesis and has been awarded by the Fanconi Anemia Research Foundation (FARF) for his commitment with the research on Fanconi anemia and dedication for patients with this disease.

 

Publications:

Lopez-Santalla M., Bueren J.A., Garin M.I.Mesenchymal stem/stromal cell-based therapy for the treatment of rheumatoid arthritis: An update on preclinical studies. EBioMedicine. 2021;69.

Hervas-Salcedo R., Fernandez-Garcia M., Hernando-Rodriguez M., Quintana-Bustamante O., Segovia J.-C., Alvarez-Silva M. et al. Enhanced anti-inflammatory effects of mesenchymal stromal cells mediated by the transient ectopic expression of CXCR4 and IL10. Stem Cell Research and Therapy. 2021;12(1).

Lopez-Santalla M., Hervas-Salcedo R., Fernandez-Garcia M., Bueren J.A., Garin M.I.Cell Therapy With Mesenchymal Stem Cells Induces an Innate Immune Memory Response That Attenuates Experimental Colitis in the Long Term. Journal of Crohn's & colitis. 2020;14(10):1424-1435.

Rio P., Navarro S., Wang W., Sanchez-Dominguez R., Pujol R.M., Segovia J.C. et al. Successful engraftment of gene-corrected hematopoietic stem cells in non-conditioned patients with Fanconi anemia. Nature Medicine. 2019;25(9):1396-1401.

Roman-Rodriguez F.J., Ugalde L., Alvarez L., Diez B., Ramirez M.J., Risueno C. et al. NHEJ-Mediated Repair of CRISPR-Cas9-Induced DNA Breaks Efficiently Corrects Mutations in HSPCs from Patients with Fanconi Anemia. Cell Stem Cell. 2019;25(5):607-621.e7.